sr141716 has been researched along with Multiple Sclerosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JZ; Chen, LL; Han, S; Pu, JB; Qian, HY; Xie, X; Zhang, FF | 1 |
| Carrillo-Salinas, FJ; Fernández-Ruiz, J; Franco, R; Gómez-Cañas, M; Goya, P; Guaza, C; Hurst, DP; Jagerovic, N; Lagartera, L; Morales, P; Navarro, G; Pazos, R; Reggio, PH | 1 |
| Killestein, J; Mathus-Vliegen, EM; Polman, CH; van Oosten, BW | 1 |
| Baker, D; Croxford, JL; Giovannoni, G; Jackson, SJ; Ledent, C; Pertwee, RG; Pryce, G; Yamamura, T | 1 |
| Baker, D; Brown, P; Croxford, JL; Huffman, JW; Layward, L; Pertwee, RG; Pryce, G | 1 |
| Baker, D; Bisogno, T; Brown, P; Croxford, JL; Di Marzo , V; Fezza, F; Khanolkar, A; Layward, L; Makriyannis, A; Pertwee, RG; Pryce, G | 1 |
| Baker, D; Bifulco, M; Bisogno, T; Bridges, D; Brooks, JW; Brown, P; Di Marzo, V; Hankey, DJ; Jaggar, SI; Ledent, C; Pryce, G; Rice, AS | 1 |
7 other study(ies) available for sr141716 and Multiple Sclerosis
| Article | Year |
|---|---|
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Ligands; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Multiple Sclerosis; Quantitative Structure-Activity Relationship; Quinolines; Receptor, Cannabinoid, CB2 | 2015 |
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
Topics: Dose-Response Relationship, Drug; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Multiple Sclerosis; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2016 |
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.
Topics: Appetite Depressants; Cannabinoid Receptor Antagonists; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2004 |
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.
Topics: Animals; Benzoxazines; Cannabinoids; Encephalomyelitis, Autoimmune, Experimental; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Morpholines; Multiple Sclerosis; Naphthalenes; Neuroprotective Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; T-Lymphocytes | 2008 |
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
Topics: Animals; Camphanes; Cannabinoids; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Multiple Sclerosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Spasm; Tremor | 2000 |
Endocannabinoids control spasticity in a multiple sclerosis model.
Topics: Amides; Animals; Arachidonic Acids; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Ethanolamines; Glycerides; Humans; Mice; Mice, Inbred Strains; Multiple Sclerosis; Palmitic Acids; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Spasm; Spinal Cord | 2001 |
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
Topics: Animals; Arachidonic Acids; Benzoxazines; Camphanes; Cannabinoid Receptor Modulators; Capsaicin; Disease Models, Animal; Dose-Response Relationship, Drug; Genotype; Mice; Mice, Inbred Strains; Mice, Knockout; Morpholines; Multiple Sclerosis; Muscle Spasticity; Naphthalenes; Pain; Pain Measurement; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2002 |